title: Update on therapies targeting HDL:  the mystery continues.
authors.forename: Salim S
authors.initials: SS
authors.lastname: Virani
authors.forename: Christie M
authors.initials: CM
authors.lastname: Ballantyne
mesh_terms: D000818:Animals; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000188:drug therapy*; D057239:Early Termination of Clinical Trials; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use; D023303:Oxazolidinones / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL; D008075:Lipoproteins, HDL; D023303:Oxazolidinones; D009525:Niacin; C530884:anacetrapib